Universal antivenom: a ray of hope against bites from the most venomous snakes

Scientists may have found a way to neutralize the venom of the world’s most dangerous snakes using an innovative and versatile antivenom.   This breakthrough combines human antibodies from an exceptionally immune donor with a small inhibitory molecule to target the neurotoxins found in the venom of 19 different species of venomous snakes.  

A Naturally Immune Donor

It all began with an extraordinary patient who voluntarily exposed himself, repeatedly and under controlled conditions, to various snake venoms. This process enabled his immune system to develop powerful and diverse antibodies against a wide range of toxins. These antibodies were then isolated, selected, and reproduced in the laboratory.  

A Two-Pronged Attack on Toxins

The treatment does not rely solely on these antibodies. Researchers combined it with a small molecule called varespladib, already known for its ability to inhibit certain enzymes with toxicity in venom. Together, these two components work synergistically to neutralize the paralyzing effects of neurotoxic venoms by blocking their action on the central nervous system.  

Promising results in animal studies

In tests conducted on mice, the cocktail proved effective against neurotoxins from snakes such as the black mamba, the Indian cobra, the king cobra, and the Australian tiger snake. It not only prevented paralysis but also saved the animals’ lives even when the treatment was administered after exposure to the venom—a crucial factor for real-world use.  

A Long-Awaited Breakthrough for High-Risk Countries

Snake bites cause more than 100,000 deaths worldwide each year, mainly in tropical countries where access to medical care is limited. Currently, antivenoms are species-specific and must be administered quickly, which complicates treatment. An antivenom effective against multiple types of venom would represent a major breakthrough in tropical medicine (easier to store, administer, and deploy in remote areas). Next step? Human clinical trials to verify the treatment’s efficacy and safety. “Our goal is to develop a treatment that does not depend on the precise identification of the snake that bit the patient. This could save thousands of lives each year, particularly in rural areas.”  

Snake Bites: A Neglected Health Emergency

Long relegated to the back burner of global public health priorities, snakebites are nonetheless a major cause of morbidity and mortality, particularly in low- and middle-income countries. According to estimates from the World Health Organization (WHO), 4.5 to 5.4 million people are bitten by venomous snakes each year, with 1.8 to 2.7 million cases of snakebite envenomation resulting in up to 138,000 deaths and approximately 400,000 cases of disabling sequelae.  

A Priority in Tropical Areas

The most affected regions are South Asia (particularly India), sub-Saharan Africa, parts of Southeast Asia, and tropical Latin America. India alone accounts for nearly half of all global snakebite-related deaths, according to several recent epidemiological studies. Risk factors include:

• proximity to snakes’ natural habitats (agricultural areas);
• lack of protective footwear;
• a lack of effective referral systems;
• insufficient antivenom supplies;
• the frequent use of traditional medicines, which delays appropriate treatment.

 

An Effective but Underutilized Treatment

Treatment relies primarily on the early administration of a specific antivenom, derived from polyclonal sera that neutralize toxins. However, the supply is fragmented, costly, and sometimes ill-suited to local species, and the supply chain is often unreliable in endemic areas. The WHO has classified snakebites as a neglected tropical disease, highlighting the lack of political will, sustainable funding, and appropriate technological solutions. The case fatality rate could, however, be drastically reduced through simple measures such as:

• increasing stocks of affordable, broad-spectrum antivenoms;
• providing training for rural health care workers;
• systems for referral and emergency medical transport;
• centralized epidemiological surveillance.

 

A Global Roadmap for 2030

In 2019, the WHO launched an ambitious strategy: to halve deaths and disabilities related to snakebites by 2030. This initiative includes:

• the development of new broad-spectrum antivenoms;
• improved clinical research;
• public-private investments in serum production;
• community awareness campaigns.

  The management of snakebites involves medical, logistical, and socioeconomic challenges. While recent scientific advances (human antibodies, molecular inhibitors) hold promise for more effective treatments, access, funding, and integration into national health policies remain the main challenges. In high-incidence areas, this is a life-threatening emergency.